We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations
We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis
We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients
Company Details
- Employees
- 4
- Founded
- -
- Address
- New York | Boston, Us
- Industry
- Biotechnology
- Website
- http://www.bakxtx.com
- Keywords
- Oncology, Apoptosis, Cell Death, Leukemias and Lymphomas, Solid tumors, Computational design, Research & Development, Drug Discovery.
- HQ
- New York | Boston
Bakx Therapeutics Questions
Bakx Therapeutics's website is http://www.bakxtx.com
Bakx Therapeutics's LinkedIn profile is https://www.linkedin.com/company/bakxtx
Bakx Therapeutics has
4 employees.
View email and phone details for 4
employees at Bakx Therapeutics.
Bakx Therapeutics's industry is
Biotechnology
Bakx Therapeutics's top competitors are
Superluminal Medicines Inc.,
Atommap,
Kestrel Therapeutics,
Ocular Melanoma Foundation,
Anchiano Therapeutics,
Ipsen,
Tarveda Therapeutics,
Tandemai,
Port Therapeutics,
Ensem Therapeutics.
Bakx Therapeutics's categories are Biotechnology
Bakx Therapeutics's founding year is 2020
